Developing an Accurate Price Model for Personalized Medicines

Randy Vogenberg, PhD, RPh

Video Categories: Pricing

Randy Vogenberg discusses the complexities of developing pricing for personalized medicine products
July 13, 2021

Offering the Appropriate Patient the Opportunity for Treatment with TRK Inhibitors

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, discuss who may and may not be appropriate candidates for TRK inhibitor therapy.

August 29, 2018

How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.